These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 21415220)

  • 41. Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway.
    Li Y; Mao Y; Brandt-Rauf PW; Williams AC; Fine RL
    Mol Cancer Ther; 2005 Jun; 4(6):901-9. PubMed ID: 15956247
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PRIMA-1 induces caspase-mediated apoptosis in acute promyelocytic leukemia NB4 cells by inhibition of nuclear factor-κB and downregulation of Bcl-2, XIAP, and c-Myc.
    Farhadi E; Safa M; Sharifi AM; Bashash D
    Anticancer Drugs; 2017 Jan; 28(1):51-58. PubMed ID: 27548348
    [TBL] [Abstract][Full Text] [Related]  

  • 43. APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma.
    Liu DS; Read M; Cullinane C; Azar WJ; Fennell CM; Montgomery KG; Haupt S; Haupt Y; Wiman KG; Duong CP; Clemons NJ; Phillips WA
    Gut; 2015 Oct; 64(10):1506-16. PubMed ID: 26187504
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer.
    Cañadas I; Rojo F; Taus Á; Arpí O; Arumí-Uría M; Pijuan L; Menéndez S; Zazo S; Dómine M; Salido M; Mojal S; García de Herreros A; Rovira A; Albanell J; Arriola E
    Clin Cancer Res; 2014 Feb; 20(4):938-50. PubMed ID: 24284055
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PRIMA-1MET induces nucleolar translocation of Epstein-Barr virus-encoded EBNA-5 protein.
    Stuber G; Flaberg E; Petranyi G; Otvös R; Rökaeus N; Kashuba E; Wiman KG; Klein G; Szekely L
    Mol Cancer; 2009 Mar; 8():23. PubMed ID: 19323829
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mutant p53 as a target for cancer treatment.
    Duffy MJ; Synnott NC; Crown J
    Eur J Cancer; 2017 Sep; 83():258-265. PubMed ID: 28756138
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models.
    Baker AF; Hanke NT; Sands BJ; Carbajal L; Anderl JL; Garland LL
    J Exp Clin Cancer Res; 2014 Dec; 33(1):111. PubMed ID: 25612802
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
    Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
    Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MicroRNA expression and clinical outcome of small cell lung cancer.
    Lee JH; Voortman J; Dingemans AM; Voeller DM; Pham T; Wang Y; Giaccone G
    PLoS One; 2011; 6(6):e21300. PubMed ID: 21731696
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PRIMA-1 and PRIMA-1
    Perdrix A; Najem A; Saussez S; Awada A; Journe F; Ghanem G; Krayem M
    Cancers (Basel); 2017 Dec; 9(12):. PubMed ID: 29258181
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Secreted Heat Shock Protein 90α Attenuated the Effect of Anticancer Drugs in Small-Cell Lung Cancer Cells Through AKT/GSK3β/β-Catenin Signaling.
    Du Y; Wu J; Luo L
    Cancer Control; 2018; 25(1):1073274818804489. PubMed ID: 30282477
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PRIMA-1(MET) induces death in soft-tissue sarcomas cell independent of p53.
    Grellety T; Laroche-Clary A; Chaire V; Lagarde P; Chibon F; Neuville A; Italiano A
    BMC Cancer; 2015 Oct; 15():684. PubMed ID: 26463477
    [TBL] [Abstract][Full Text] [Related]  

  • 53. APR-246 as a radiosensitization strategy for mutant p53 cancers treated with alpha-particles-based radiotherapy.
    Michaeli O; Luz I; Vatarescu M; Manko T; Weizman N; Korotinsky Y; Tsitrina A; Braiman A; Arazi L; Cooks T
    Cell Death Dis; 2024 Jun; 15(6):426. PubMed ID: 38890278
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibition of p62/SQSTM1 sensitizes small-cell lung cancer cells to cisplatin-induced cytotoxicity by targeting NEDD9 expression.
    Xu L; Xu F; Kong Q; Yang T; Tan D; Zhang X; Li N; Zhao S; Zhao J; Li M
    Mol Carcinog; 2020 Aug; 59(8):967-979. PubMed ID: 32424979
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis.
    Lambert JM; Moshfegh A; Hainaut P; Wiman KG; Bykov VJ
    Oncogene; 2010 Mar; 29(9):1329-38. PubMed ID: 19946333
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PRIMA-1Met induces apoptosis in Waldenström's Macroglobulinemia cells independent of p53.
    Sobhani M; Abdi J; Manujendra SN; Chen C; Chang H
    Cancer Biol Ther; 2015; 16(5):799-806. PubMed ID: 25803193
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
    Sen T; Rodriguez BL; Chen L; Corte CMD; Morikawa N; Fujimoto J; Cristea S; Nguyen T; Diao L; Li L; Fan Y; Yang Y; Wang J; Glisson BS; Wistuba II; Sage J; Heymach JV; Gibbons DL; Byers LA
    Cancer Discov; 2019 May; 9(5):646-661. PubMed ID: 30777870
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reactivation of p53 mutants by prima-1 [corrected] in thyroid cancer cells.
    Messina RL; Sanfilippo M; Vella V; Pandini G; Vigneri P; Nicolosi ML; Gianì F; Vigneri R; Frasca F
    Int J Cancer; 2012 May; 130(10):2259-70. PubMed ID: 21647879
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evodiamine induces G2/M arrest and apoptosis via mitochondrial and endoplasmic reticulum pathways in H446 and H1688 human small-cell lung cancer cells.
    Fang C; Zhang J; Qi D; Fan X; Luo J; Liu L; Tan Q
    PLoS One; 2014; 9(12):e115204. PubMed ID: 25506932
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007.
    Synnott NC; Bauer MR; Madden S; Murray A; Klinger R; O'Donovan N; O'Connor D; Gallagher WM; Crown J; Fersht AR; Duffy MJ
    Cancer Lett; 2018 Feb; 414():99-106. PubMed ID: 29069577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.